Table 2 Univariate and multivariate analyses of recurrence-free survival (n = 62)

Age (> 60 years vs. ≤ 60 years)

1.88 (0.57–6.19)

0.298

Sex (men vs. women)

0.62 (0.21–1.85)

0.389

Site of tumor (gastric vs. non-gastric)

1.19 (0.40–3.57)

0.752

Size (> 5 cm vs. ≤ 5 cm)

3.83 (1.05–13.98)

0.042*

Mitotic count per HPFs (> 5 vs. ≤ 5)

4.27 (1.31–13.89)

0.016*

Resection (R1 vs. R0)

2.48 (0.32–19.45)

0.389

Modified NIH consensus criteria (high-risk group vs. the other risk groups)

4.67 (1.28–16.98)

0.019*

0.34 (0.05–2.26)

0.261

0.33 (0.048–2.24)

0.255

Adjuvant imatinib treatment (yes vs. no)

4.89 (1.62–14.77)

0.005*

1.28 (0.34–4.77)

0.715

1.39 (0.36–5.35)

0.632

SUVmax (≥ 7.04 vs. < 7.04)

13.46 (2.98–60.75)

0.001*

4.44 (0.79–25.00)

0.091

3.43 (0.53–22.17)

0.196

MTV (≥ 54.76 cm³ vs. < 54.76 cm³)

19.79 (4.37–89.67)

< 0.001*

17.69 (2.03–154.17)

0.009*

TLG (≥ 228.79 g vs. < 228.79 g)

22.24 (4.91–100.77)

< 0.001*

20.48 (2.19–191.16)

0.008*